Taofeek Kunle Owonikoko

List of Publications by Year
in descending order

228 papers	16,648 citations	23567 58 h-index	18130 120 g-index
232 all docs	232 docs citations	232 times ranked	25593 citing authors

#	Article	IF	Citations
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
2	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 341-351.	27.0	997
3	Rescue of exhausted CD8 T cells by PD-1â€“targeted therapies is CD28-dependent. Science, 2017, 355, 1423-1427.	12.6	753
4	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
5	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1â€“targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4993-4998.	7.1	614
6	Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 2007, 25, 5570-5577.	1.6	488
7	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
8	Lung cancer: New biological insights and recent therapeutic advances. Ca-A Cancer Journal for Clinicians, 2011, 61, 91-112.	329.8	413
9	Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth. Cancer Cell, 2012, 22, 585-600.	16.8	329
10	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
11	Comparison of the toxicity profile of PDâ€1 versus PDâ€L1 inhibitors in nonâ€“small cell lung cancer: A systematic analysis of the literature. Cancer, 2018, 124, 271-277.	4.1	265
12	Adenoid cystic carcinoma of the head and neck. Cancer, 2012, 118, 4444-4451.	4.1	251
13	Current approaches to the treatment of metastatic brain tumours. Nature Reviews Clinical Oncology, 2014, 11, 203-222.	27.6	233
14	The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. Molecular Cell, 2018, 69, 87-99.e7.	9.7	217
15	Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 3-10.	3.8	173
16	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. Cancer, 2013, 119, 2602-2610.	4.1	166
17	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	1.1	156
18	Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Frontiers in Oncology, 2020, 10, 1000.	2.8	152

#	Article	IF	Citations
19	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology, 2021, 39, 1349-1359.	1.6	147
20	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2019, 14, 876-889.	1.1	141
21	Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2013, 12, 2200-2212.	4.1	137
22	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters, 2016, 380, 494-504.	7.2	137
23	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	28.9	135
24	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. Journal of Clinical Oncology, 2019, 37, 222-229.	1.6	133
25	The prognostic and predictive impact of inflammatory biomarkers in patients who have advancedâ€stage cancer treated with immunotherapy. Cancer, 2019, 125, 127-134.	4.1	120
26	Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer, 2012, 118, 4571-4578.	4.1	119
27	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
28	A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 866-872.	1.1	117
29	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2016, 17, 1661-1671.	10.7	115
30	Small-molecule Bax agonists for cancer therapy. Nature Communications, 2014, 5, 4935.	12.8	110
31	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell, 2015, 27, 852-863.	16.8	108
32	Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Annals of Oncology, 2019, 30, 1613-1621.	1.2	107
33	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 128-137.	0.8	105
34	Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical Cancer Research, 2017, 23, 6567-6579.	7.0	103
35	Postoperative Radiotherapy is Associated with Better Survival in Nonâ€“Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. Journal of Thoracic Oncology, 2015, 10, 462-471.	1.1	101
36	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discovery, 2016, 6, 601-611.	9.4	97

#	Article	IF	Citations
37	Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis. Oncology, 2011, 81, 12-20.	1.9	96
38	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. Journal of Thoracic Oncology, 2020, 15, 274-287.	1.1	95
39	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell, 2018, 34, 315-330.e7.	16.8	94
40	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1120.	7.1	93
41	An update on the immune landscape in lung and head and neck cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 505-517.	329.8	93
42	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cellâ€“Inflamed Phenotype. Journal of Thoracic Oncology, 2021, 16, 464-476.	1.1	93
43	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer, 2016, 122, 766-772.	4.1	92
44	Altered Glutamine Metabolism and Therapeutic Opportunities for Lung Cancer. Clinical Lung Cancer, 2014, 15, 7-15.	2.6	88
45	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer, 2019, 19, 857.	2.6	88
46	Vorinostat increases carboplatin and paclitaxel activity in nonâ€small cell lung cancer cells. International Journal of Cancer, 2010, 126, 743-755.	5.1	84
47	Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. Journal of Nuclear Medicine, 2002, 43, 678-92.	5.0	81
48	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of Translational Medicine, 2016, 14, 111.	4.4	78
49	Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 2014, 3, 1579-1594.	2.8	74
50	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular Cell, 2016, 64, 859-874.	9.7	73
51	Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Advances in Therapy, 2021, 38, 350-365.	2.9	71
52	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e57-e64.	2.6	68
53	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e395-e401.	3.8	67
54	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemotherapy and Pharmacology, 2016, 77, 155-162.	2.3	66

#	Article	IF	Citations
55	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer, 2020, 126, 575-582.	4.1	65
56	The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE, 2011, 6, e20899.	2.5	64
57	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clinical Lung Cancer, 2017, 18, 286-292.	2.6	64
58	Atypical Carcinoid Tumor of the Lung: A Surveillance, Epidemiology, and End Results Database Analysis. Journal of Thoracic Oncology, 2015, 10, 479-485.	1.1	63
59	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer. Cancer Research, 2013, 73, 5485-5496.	0.9	62
60	Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study. Cancer Prevention Research, 2014, 7, 283-291.	1.5	62
61	Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death and Differentiation, 2014, 21, 1160-1169.	11.2	58
62	HPV-associated lung cancers: an international pooled analysis. Carcinogenesis, 2014, 35, 1267-1275.	2.8	57
63	Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biology and Therapy, 2011, 12, 549-555.	3.4	56
64	Rising Incidence of Mucosal Melanoma of the Head and Neck in the United States. Journal of Skin Cancer, 2012, 2012, 1-6.	1.2	55
65	Small Cell Lung Cancer: Therapies and Targets. Seminars in Oncology, 2014, 41, 133-142.	2.2	55
66	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. Journal of Molecular Diagnostics, 2016, 18, 299-315.	2.8	55
67	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.	4.2	55
68	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Letters, 2012, 325, 139-146.	7.2	54
69	NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCÎ¹/FAK loop. Cancer Letters, 2012, 318, 106-113.	7.2	53
70	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer, 2014, 120, 3940-3951.	4.1	53
71	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced Î²-TrCP degradation. Oncogene, 2019, 38, 6270-6282.	5.9	53
72	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biology and Therapy, 2012, 13, 272-280.	3.4	52

#	Article	IF	Citations
73	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOGâ€“ACRIN Cancer Research Group (E2511). Lung Cancer, 2015, 89, 66-70.	2.0	52
74	Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. Lung Cancer, 2012, 77, 331-338.	2.0	51
75	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e395-e401.	3.8	51
76	Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biological Psychiatry, 2004, 55, 766-771.	1.3	49
77	c-Myc Suppression of DNA Double-strand Break Repair. Neoplasia, 2012, 14, 1190-IN35.	5.3	48
78	Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy. Journal of Clinical Investigation, 2017, 128, 500-516.	8.2	48
79	Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation. Journal of Biological Chemistry, 2013, 288, 13215-13224.	3.4	47
80	Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Nonâ€“Small Cell Lung Cancer: A Phase I Study. Journal of Thoracic Oncology, 2017, 12, 1687-1695.	1.1	47
81	Immune checkpoint inhibitors in small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S460-S467.	1.4	46
82	Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 433-441.	1.6	45
83	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
84	Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nature Clinical Practice Oncology, 2007, 4, 491-495.	4.3	44
85	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist, 2020, 25, e528-e535.	3.7	44
86	Racial disparities in squamous cell carcinoma of the oral tongue among women: A SEER data analysis. Oral Oncology, 2015, 51, 586-592.	1.5	43
87	Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. International Journal of Radiation Oncology Biology Physics, 2020, 108, 304-313.	0.8	42
88	Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 45-56.	4.1	40
89	Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase. Cancer Research, 2014, 74, 212-223.	0.9	40
90	Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Letters, 2015, 364, 70-78.	7.2	40

#	Article	IF	Citations
91	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptorâ€mutant nonâ€“small cell lung cancer cells to osimertinib. Cancer, 2020, 126, 1339-1350.	4.1	40
92	Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2021, 17, 965-977.	2.4	40
93	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-NaÃ¯ve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clinical Cancer Research, 2021, 27, 3884-3895.	7.0	40
94	Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 369-372.	1.1	37
95	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer, 2016, 122, 50-60.	4.1	37
96	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer, 2010, 116, 3903-3909.	4.1	36
97	Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treatment Reviews, 2016, 50, 89-98.	7.7	36
98	Nextâ€generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. Cancer, 2017, 123, 3681-3690.	4.1	36
99	Comparative analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study. Journal of Pathology, 2001, 193, 155-161.	4.5	35
100	Oncogenic role of EAPII in lung cancer development and its activation of the MAPKâ€“ERK pathway. Oncogene, 2011, 30, 3802-3812.	5.9	35
101	Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. Journal of Biological Chemistry, 2012, 287, 257-267.	3.4	35
102	Human immunodeficiency virusâ€associated lung cancer in the era of highly active antiretroviral therapy. Cancer, 2012, 118, 164-172.	4.1	35
103	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer, 2017, 123, 3476-3485.	4.1	35
104	Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2021, 39, 8510-8510.	1.6	35
105	Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology, 2014, 8, 66-72.	2.6	34
106	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Supportive Care in Cancer, 2016, 24, 1789-1793.	2.2	34
107	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. , 2020, 8, e001302.		34
108	Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEERâ€“Medicare Analysis. Oncologist, 2013, 18, 600-610.	3.7	33

#	Article	IF	Citations
109	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist, 2016, 21, 1163-1164e.	3.7	32
110	Overcoming acquired resistance of epidermal growth factor receptorâ€•mutant nonâ€“small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer, 2020, 126, 2024-2033.	4.1	32
111	Intratumoral Genetic Heterogeneity in Barrett Adenocarcinoma. American Journal of Clinical Pathology, 2002, 117, 558-566.	0.7	30
112	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2019, 84, 1289-1301.	2.3	29
113	EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene, 2020, 39, 4798-4813.	5.9	29
114	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer Research, 2021, 81, 4822-4834.	0.9	29
115	Maintenance Therapy for Advanced Non-small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus. Clinical Cancer Research, 2010, 16, 2496-2504.	7.0	28
116	The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Letters, 2013, 338, 229-238.	7.2	28
117	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical Cancer Research, 2019, 25, 6119-6126.	7.0	28
118	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. Cancer Research, 2020, 80, 2380-2393.	0.9	28
119	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. Journal of Clinical Investigation, 2019, 129, 2431-2445.	8.2	28
120	In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. Journal of Nuclear Medicine, 2004, 45, 94-100.	5.0	27
121	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Molecular Aspects of Medicine, 2015, 45, 55-66.	6.4	26
122	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. Cancer, 2015, 121, 1772-1778.	4.1	26
123	Guideline-concordant Care Improves Overall Survival for Locally Advanced Nonâ€“Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. Clinical Lung Cancer, 2017, 18, 706-718.	2.6	26
124	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptorâ€“mutant lung cancers. Cancer, 2020, 126, 3788-3799.	4.1	26
125	Overcoming acquired resistance of EGFRâ€•mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular Oncology, 2020, 14, 882-895.	4.6	26
126	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2018, 17, 710-716.	4.1	25

#	Article	IF	Citations
127	Mcl-1 Interacts with Akt to Promote Lung Cancer Progression. Cancer Research, 2019, 79, 6126-6138.	0.9	25
128	Stereotactic Body Radiotherapy for Early-stage Nonâ€“small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. Clinical Lung Cancer, 2017, 18, 551-558.e6.	2.6	24
129	Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Research, 2017, 77, 3001-3012.	0.9	24
130	Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer, 2018, 124, 775-784.	4.1	24
131	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British Journal of Cancer, 2013, 108, 762-765.	6.4	22
132	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 1859-1868.	7.0	22
133	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer, 2015, 88, 80-84.	2.0	22
134	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. Journal of Clinical Investigation, 2019, 129, 4110-4123.	8.2	22
135	CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC. Clinical Cancer Research, 2013, 19, 1603-1611.	7.0	21
136	Taxanes: vesicants, irritants, or just irritating?. Therapeutic Advances in Medical Oncology, 2014, 6, 16-20.	3.2	21
137	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head and Neck, 2019, 41, 1490-1498.	2.0	21
138	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clinical Cancer Research, 2022, 28, 1540-1548.	7.0	21
139	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review. Oral Oncology, 2014, 50, 888-894.	1.5	20
140	Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 2015, 10, 1142-1147.	1.1	19
141	Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation. Nucleic Acids Research, 2015, 43, 960-972.	14.5	19
142	OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 2017, 12, S261-S262.	1.1	19
143	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular Cancer Research, 2021, 19, 1622-1634.	3.4	19
144	Discovery of Small Molecule Bak Activator for Lung Cancer Therapy. Theranostics, 2021, 11, 8500-8516.	10.0	19

#	Article	IF	Citations
145	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic Advances in Medical Oncology, 2015, 7, 56-62.	3.2	18
146	Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. Cancer Cytopathology, 2018, 126, 236-242.	2.4	18
147	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repairâ€“Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical Lung Cancer, 2021, 22, 187-194.e1.	2.6	18
148	Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene, 2021, 40, 6653-6665.	5.9	17
149	Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell, 2022, 185, 1974-1985.e12.	28.9	17
150	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemporary Clinical Trials, 2015, 43, 133-141.	1.8	16
151	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: AÂPropensity Score-Matched Analysis of the National Cancer Database. Clinical Lung Cancer, 2019, 20, 484-493.e6.	2.6	16
152	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage <scp>Colony-Stimulating</scp> Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist, 2021, 26, e1508-e1513.	3.7	16
153	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget, 2015, 6, 8974-8987.	1.8	15
154	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Theranostics, 2021, 11, 3964-3980.	10.0	15
155	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer, 2013, 119, 1503-1511.	4.1	14
156	Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncology, 2022, 18, 2639-2649.	2.4	14
157	Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. BioMedical Engineering OnLine, 2011, 10, 97.	2.7	13
158	Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. Oncologist, 2013, 18, 1262-1269.	3.7	13
159	Small Cell Lung Cancer in Elderly Patients: A Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 333-344.	4.9	12
160	MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. Journal of Thoracic Oncology, 2017, 12, S406-S407.	1.1	12
161	Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV. Frontiers in Immunology, 2019, 10, 2267.	4.8	12
162	Efficacy and safety of immune checkpoint blockade in selfâ€identified Black patients with advanced nonâ€“small cell lung cancer. Cancer, 2020, 126, 5040-5049.	4.1	12

#	Article	IF	Citations
163	Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. PLoS ONE, 2021, 16, e0254125.	2.5	12
164	Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. Advances in Therapy, 2021, 38, 5431-5451.	2.9	12
165	A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget, 2017, 8, 81441-81454.	1.8	12
166	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	12
167	The Role of Cetuximab in the Management of Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, 230-238.	2.6	11
168	Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs. Cancer, 2015, 121, 3390-3392.	4.1	11
169	Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene, 2016, 35, 459-467.	5.9	11
170	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational New Drugs, 2019, 37, 1198-1206.	2.6	11
171	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung Cancer, 2020, 150, 26-35.	2.0	11
172	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clinical Cancer Research, 2020, 26, 5860-5868.	7.0	11
173	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, TPS8577-TPS8577.	1.6	11
174	Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotropic hormone-producing pancreatic neuroendocrine cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 295-300.	3.2	10
175	Upholding the Principles of Autonomy, Beneficence, and Justice in Phase I Clinical Trials. Oncologist, 2013, 18, 242-244.	3.7	10
176	Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials. Contemporary Clinical Trials, 2014, 37, 322-332.	1.8	10
177	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 240-244.	9.4	10
178	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
179	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2497-2505.	7.0	9
180	Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2021, 87, 689-700.	2.3	9

#	Article	IF	Citations
181	Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene, 2022, 41, 1691-1700.	5.9	9
182	Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups. Head and Neck, 2020, 42, 678-687.	2.0	8
183	Patientâ€reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer Medicine, 2020, 9, 7511-7523.	2.8	8
184	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology, 2018, 95, 138-146.	1.9	7
185	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS ONE, 2019, 14, e0206309.	2.5	7
186	Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)â€"Phase 1b results.. Journal of Clinical Oncology, 2017, 35, 8568-8568.	1.6	7
187	Development and testing of a tool to assess patient preferences for phase I clinical trial participation. Psycho-Oncology, 2015, 24, 835-838.	2.3	6
188	Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. PLoS ONE, 2017, 12, e0170187.	2.5	6
189	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British Journal of Cancer, 2020, 123, 1228-1234.	6.4	6
190	Integrating Genetic and Genomic Testing Into Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e259-e263.	3.8	6
191	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Cancer, 2018, 124, 3586-3595.	4.1	5
192	Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 331-336.	1.3	5
193	Optimum health and inhibition of cancer progression by microbiome and resveratrol. Frontiers in Bioscience - Landmark, 2021, 26, 496-517.	3.0	5
194	Physician Communication and Patient Understanding of Molecular Testing Terminology. Oncologist, 2021, 26, 934-940.	3.7	5
195	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2020, 38, TPS9080-TPS9080.	1.6	5
196	Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer. Oncotarget, 2016, .	1.8	5
197	The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). Current Treatment Options in Oncology, 2008, 9, 313-325.	3.0	4
198	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. Case Reports in Oncology, 2020, 13, 239-244.	0.7	4

#	Article	IF	Citations
199	A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease. World Journal of Oncology, 2015, 6, 416-420.	1.5	4
200	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. Cancers, 2022, 14, 2639.	3.7	4
201	Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEERâ€“Medicare Database Analysis. Cancers, 2022, 14, 3206.	3.7	4
202	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. Therapeutic Advances in Medical Oncology, 2010, 2, 229-235.	3.2	3
203	Survival Analysis of Patients With Stage I Nonâ€“Small-Cell Lung Cancer Using Clinical and DNA Repair Pathway Expression Variables. Clinical Lung Cancer, 2013, 14, 128-138.	2.6	3
204	E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 171-180.	2.3	3
205	Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer. Journal of Clinical Oncology, 2015, 33, 534-536.	1.6	3
206	PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy. Journal of Thoracic Oncology, 2016, 11, S306-S307.	1.1	3
207	Prognostic significance of an invasive leader cellâ€“derived mutation cluster on chromosome 16q. Cancer, 2020, 126, 3140-3150.	4.1	3
208	Interactive Software â€œIsotonic Design using Normalized Equivalent Toxicity Score (ID-NETSÂ©TM)â€•for Cancer Phase I Clinical Trials. Open Medical Informatics Journal, 2013, 7, 8-17.	1.0	3
209	Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials. Psycho-Oncology, 2021, 30, 1739-1744.	2.3	2
210	A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2012, 30, 2576-2576.	1.6	2
211	The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. American Journal of Cancer Research, 2020, 10, 3316-3327.	1.4	2
212	Preoperative therapy for early-stage NSCLC: opportunities and challenges. Oncology, 2009, 23, 886, 889, 892.	0.5	2
213	P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology, 2017, 12, S696.	1.1	1
214	Immunotherapy of lung cancer. Journal of Thoracic Disease, 2018, 10, S395-S396.	1.4	1
215	The clinical conundrum of managing relapsed small cell lung cancer. Cancer, 2019, 125, 1022-1026.	4.1	1
216	Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients. Cancer Research, 2015, 75, 1317-1317.	0.9	1

#	Article	IF	Citations
217	Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.. Journal of Clinical Oncology, 2019, 37, 9042-9042.	1.6	1
218	Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. SKIN the Journal of Cutaneous Medicine, 2019, 3, 169.	0.3	1
219	Minimal progress, potential promise in small-cell lung cancer. Oncology, 2008, 22, 1495-6.	0.5	1
220	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. World Journal of Oncology, 2015, 6, 349-354.	1.5	0
221	Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, E438-E439.	0.8	0
222	Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older. International Journal of Radiation Oncology Biology Physics, 2016, 96, E468.	0.8	0
223	P2.02-015 Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S855-S856.	1.1	0
224	P1.07-014 Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis. Journal of Thoracic Oncology, 2017, 12, S703-S704.	1.1	0
225	Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer. Oncologist, 2020, 25, e1586-e1588.	3.7	0
226	SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation. Journal of the Endocrine Society, 2020, 4, .	0.2	0
227	Abstract 5428: Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines. , 2010, , .		0
228	Lung cancer in the elderly: what's age got to do with it?. Oncology, 2010, 24, 1120, 1122, 1129.	0.5	0